With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

Kyle LaHucik

Senior Reporter

Seattle startup Outpace Bio, a Lyell Immunopharma spinout using AI to design proteins for solid tumor cell therapies, has raised a $144 million Series B …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

FDA hits Camurus with CRL for acromegaly therapy over manufacturing issues

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

Starboard takes activist stake in J&J consumer spinout Kenvue

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

With $144M Se­ries B, Out­pace Bio beats fund­ing goal for sol­id tu­mor cell ther­a­pies

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies